Using special polymers to improve targeted cancer treatments
Official title: Supramolecular polymers for targeted protein degradation
Funded at University of Southern Mississippi · NIH-10690750 · Data updated 2026-11-12
This study is looking at new ways to make cancer treatments more effective by improving how they target and remove harmful proteins in your body, which could lead to better options for patients dealing with cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern Mississippi NIH-funded |
| Lab location | 1 site (Hattiesburg, United States) |
| Project start | September 1, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $74,000 |
| NIH project number | 5R03EB033704-02 |
| Project ID | NIH-10690750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that exhibit drug resistance or have previously been considered untreatable due to the nature of their protein targets.
✕Less likely to help
Patients with early-stage cancers that are easily treatable with existing therapies may not receive significant benefit from this research.
What this research studies
This research explores innovative methods to enhance targeted protein degradation therapies, which aim to selectively eliminate harmful proteins associated with diseases like cancer. By utilizing advanced synthetic biology techniques and novel supramolecular polymers, the project seeks to improve how these therapies are delivered to cells, ensuring better specificity and internalization. The goal is to overcome current challenges in drug resistance and unlock new therapeutic targets that were previously considered undruggable. Patients may benefit from more effective treatments that can address their specific cancer types.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade problematic proteins, potentially improving patient outcomes.
How similar studies have gone: Other research has shown promise in using targeted protein degradation strategies, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
University of Southern Mississippi
Hattiesburg, United States Active
Researchers
- Principal investigator: Clemons, Tristan — University of Southern Mississippi
- Study coordinator: Clemons, Tristan
Related research
Other NIH-funded projects on the same topics.
-
Developmental Research Project Core (MS INBRE)
A program to grow biomedical research in Mississippi by helping undergraduate institutions recruit faculty, train students, and upgrade lab spaces and equipment.
-
Community Engagement and Training Core supports Mississippi researchers
A grant to build and strengthen community-based research partnerships in Mississippi to train scientists, students, and community groups to work together on health improvements.
-
Instrumentation and Services Core to power multiomics, gene editing, and imaging research
This grant funds an Instrumentation and Services Core to help Mississippi researchers use advanced tools for genomics, proteomics, metabolomics, gene editing, cellular assays, and imaging.
-
Data Science Core supports biomedical researchers with AI, ML, and bioinformatics in Mississippi
A Mississippi research center provides advanced data analysis and AI-powered tools to help scientists study biological and epidemiological data.
-
Administrative Core to strengthen Mississippi’s biomedical research network
This grant supports a statewide network to build research capacity in Mississippi, connect colleges and communities, and train students for health-related careers.
-
Mississippi network to boost Biomedical Research across schools
A statewide program helps Mississippi colleges collaborate to build biomedical research capacity and train a strong workforce focused on cancer, infectious disease, and obesity.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.